Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 20, 2018. The report discloses transactions involving Persons Discharging Managerial Responsibilities (PDMRs) selling shares to meet tax liabilities following the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on specific share transaction details.
| Transaction Date | Instrument | Price | Total Volume |
|---|---|---|---|
| February 16, 2018 | Ordinary Shares (GBP) | £13.0726 | 239,832 |
| February 16, 2018 | American Depositary Shares (USD) | $37.4803 | 46,024 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It reports routine compliance disclosures regarding executive share sales.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transactions are described as sales to meet tax liabilities, which are standard compliance events.
Investor Verification Points
- Verify the total number of shares sold by PDMRs to ensure alignment with the vesting schedule of the 2009 Performance Share Plan.
- Confirm the transaction prices (£13.0726 for Ordinary Shares and $37.4803 for ADSs) against the market closing price on February 16, 2018.
- Note that these sales were executed on the London Stock Exchange (XLON) and New York Stock Exchange (XNYS).
- Identify that the largest single transaction was by Dr. P J T Vallance (President, R&D), who sold 73,783 Ordinary Shares.